Parathyroid carcinoma

Journal of Bone and Mineral Research

Volumn 23, Issue 12, 2008, Pages 1869-1880

  Marcocci, Claudio ^a   Cetani, Filomena ^a   Rubin, Mishaela R ^b   Silverberg, Shonni J ^b   Pinchera, Aldo ^a   Bilezikian, John P ^b  

^a UNIVERSITY OF PISA   (Italy)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIMIMETIC AGENT; CALCITONIN; CALCIUM; CALCIUM SENSING RECEPTOR; CHLORMETHINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; CINACALCET; CYCLIN D1; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN; LOOP DIURETIC AGENT; MITHRAMYCIN; OCTREOTIDE; PAMIDRONIC ACID; PARAFIBROMIN PROTEIN; PARATHYROID HORMONE; R 568; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOSTERISM; ANEMIA; BONE PAIN; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL STRAIN 3T3; CELL STRAIN HEK293; CELL THERAPY; CYSTIC FIBROSIS; DENDRITIC CELL; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; EARLY DIAGNOSIS; FATIGUE; FRACTURE; GENE; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HRPT2 GENE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IRRADIATION; KIDNEY CALCIFICATION; KIDNEY COLIC; KIDNEY DISEASE; LYMPHADENECTOMY; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NECK TUMOR; NEPHROLITHIASIS; ONCOGENE; OSTEITIS; OSTEOPENIA; PANCREATITIS; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PEPTIC ULCER; POLYDIPSIA; POLYURIA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SURGICAL APPROACH; SURVIVAL RATE; THYROGLOBULIN BLOOD LEVEL; TREATMENT DURATION; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; MODELS, GENETIC; MUTATION; PARATHYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 56749107613     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081018     Document Type: Review

References (108)

1. Shane E 2001 Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2:485-493.
2. De Lellis RA 2005 Parathyroid carcinoma. An overview. Adv Anat Pathol 12:53-61.
3. Cetani F, Pardi E, Banti C, Borsari S, Ambrogini E, Vignali E, Cianferotti L, Viccica G, Pinchera A, Marcocci C 2008 HRPT2 gene analysis and diagnosis of parathyroid carcinoma. Expert Rev Endocrinol Metab 3:377-389.
4. Bondenson L, Grimelius L, DeLellis RA, Lloyd R, Akerstrom G, Larsson C, Arnold A, Eng C, Shane E, Bilezikian JP 2004. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds.) Pathology and Genetics. Tumors of Endocrine Organs. WHO Classification of Tumours, IARC Press, Lyon, France, pp. 124-127.
5. Shane E 2001 Parathyroid carcinoma. In: Bilezikian JP, Marcus R, Levine MA (eds.) The Parathyroids. Basic and Clinical Concepts, 2nd ed. Academic Press, San Diego, CA, USA, pp. 515-525.
6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1999 Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1999: A National Cancer Database report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86:538-544.
7. Favia G, Lumachi F, Polistina F, D'Amico DF 1998 Parathyroid carcinoma: Sixteen new cases and suggestions for correct management. World J Surg 22:1225-1230.
8. Obara T, Fujimoto Y 1991 Diagnosis and treatment of patients with parathyroid carcinoma: An update and review. World J Surg 15:738-744.
9. Ireland J, Fleming S, Levison D, Cattell W, Baker L 1985 Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 38:1114-1118.
10. Christmas TJ, Chapple CR, Noble JG, Milroy EJ, Cowie AG 1988 Hyperparathyroidism after neck irradiation. Br J Surg 75:873-874.
11. Cohen J, Gierlowski TC, Schneider AB 1990 A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 264:581-584.
12. Schneider AB, Gierlowski TC, Shore-Freedman E, Stovall M, Ron E, Lubin J 1995 Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab 80:254-257.
13. Rasmuson T, Damber L, Johansson L, Johansson R, Larsson LG 2002 Increased incidence of parathyroid adenomas following X-ray treatment of benign diseases in the cervical spine in adult patients. Clin Endocrinol (Oxf) 57:731-734.
14. Berland Y, Olmer M, Lebreuil G, Grisoli J 1982 Parathyroid carcinoma, adenoma and hyperplasia in a case of chronic renal insufficiency on dialysis. Clin Nephrol 18:154-158.
15. Boyle NH, Ogg CS, Hartley RB, Owen WJ 1999 Parathyroid carcimoma secondary to prolonged hyperplasia in chronic renal failure and celiac disease. Eur J Surg Oncol 25:100-103.
16. Streeten EA, Weinstein LS, Norton JA, Mulvihill JJ, White BJ, Friedman E, Jaffe G, Brandi ML, Stewart K, Zimering MB, Spiegel AM, Aurbach GD, Marx SJ 1992 Studies in a kindred with parathyroid carcinoma. J Clin Endocrinol Metab 75:362-366.
17. Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjöld M, Peters TJ, Larsson C 1993 Familial isolated hyperparathyroidism: A distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 77:1485-1489.
18. Yoshimoto K, Endo H, Tsuyuguchi M, Tanaka C, Kimura T, Iwahana H, Kato G, Sano T, Itakura M 1998 Familial isolated primary hyperparathyroidism with parathyroid carcinomas: Clinical and molecular features. Clin Endocrinol (Oxf) 48:67-72.
19. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR Jr, Chen CC, Chang R, Chandrasekharappa SC, Collins FS 2002 Hyperparathyroidism in hereditary syndromes: Special expressions and special managements. J Bone Miner Res 17:S2;N37-N43.
20. Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD, Teh BT 2003 Hyperparathyroidism-jaw tumour syndrome. J Intern Med 253:634-642.
21. Mallette LE, Malini S, Rappaport MP, Kirkland JL 1987 Familial cystic parathyroid adenomatosis. Ann Intern Med 107:54-60.
22. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H III, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, The BT, Larsson C, Hobbs MR 2002 HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumors syndrome. Nat Genet 32:676-680.
23. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ 2002 Familial isolated hyperparathyroidism: Clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81:1-26.
24. Dionisi S, Minisola S, Pepe J, De Geronimo S, Paglia F, Memeo L, Fitzpatrick LA 2002 Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: Presentation as hypercalcemic crisis. Mayo Clin Proc 77:866-869.
25. Agha A, Carpenter R, Bhattacharya S, Edmonson SJ, Carlsen E, Monson JP 2007 Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: Two case reports of an unrecognized entity. J Endocrinol Invest 30:145-149.
26. Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H 2007 Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 67:370-376.
27. Jenkins PJ, Satta MA, Simmgen M, Drake WM, Williamson C, Lowe DG, Britton K, Chew SL, Thakker RV, Besser GM 1997 Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol (Oxf) 47:747-751.
28. Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y, Saucier K 2002 Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 17:S2;N30-N36.
29. Cetani F, Pardi E, Borsari S, Lemmi M, Ambrogini E, Vignali E, Cianferotti L, Pinchera M, Marcocci C 2006 Parathyroid tumorigenesis. Clin Cases Miner Bone Metab 3:123-431.
30. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A 1994 Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330:757-761.
31. Dotzenrath C, The T, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C 1996 Allelic loss of the retinoblastoma tumor suppressor gene: A marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 8:3194-3196.
32. Pearce SH, Trump D, Wooding W, Sheppard MN, Clayton RN, Thakker RV 1996 Loss of heterozygosity study at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumors. Clin Endocrinol (Oxf) 45:195-200.
33. Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C 2004 A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 60:99-406.
34. Shattuck TM, Kim TS, Costa J, Yandell DW, Imanishi Y, Palanisamy N, Gaz RD, Shoback D, Clark OH, Monchik JM, Wierman ME, Hollenberg A, Tojo K, Chaganti RS, Arnold A 2003 Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 59:180-189.
35. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT 2003 HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657-663.
36. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A 2003 Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722-4729.
37. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C 2004 Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: Germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89:5583-5591.
38. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ 2004 Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89:96-102.
39. Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S, Hill P, Perry-Keene D, Learoyd D, Robinson B, Birdsey P, Mackenzie E, Teh BT, Prins JB, Cardinal J 2004 Genetic testing in familial isolated hyperparathyroidism: Unexpected results and their implications. J Med Genet 41:155-460.
40. Villablanca A, Calender A, Forsberg L, Höög A, Cheng JD, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson AL, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG, Larsson C 2004 Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41:e32.
41. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceição Pereira M, Davie MW, Dudley N, Leite V, Sadler GP, Seller A, Thakker RV 2006 Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 64:299-306.
42. Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M, Tahara H, Fujisawa M, Kamata N, Fujisawa K, Yashiro T, Nagao D, Golam HM, Sano T, Noguchi S, Yoshimoto K 2006 Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 65:9-16.
43. Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, Minisola S, Mascia ML, D'Agruma L, Cole DE 2006 Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: Implications for cancer surveillance. J Clin Endocrinol Metab 91:2827-2832.
44. Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A, Carpenter TO 2006 Surveillance for early detection of aggressive parathyroid disease: Carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21:1666-1671.
45. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C 2007 Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156:547-554.
46. Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, Morreau H 2007 Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 67:370-376.
47. Hewitt KM, Sharma PK, Samowitz W, Hobbs M 2007 Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 116:928-933.
48. Krebs LJ, Shattuck TM, Arnold A 2005 HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90:5015-5017.
49. Chaudhary K, Deb S, Moniaux N, Ponnusamy MP, Batra SK 2007 Human RNA polymerase II-associated factor complex: Dysregulation in cancer. Oncogene 26:7499-7507.
50. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M 2005 The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol 25:612-620.
51. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D, Krek W 2005 The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 25:5052-5060.
52. Hahn MA, Marsh DJ 2005 Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 24:6241-6248.
53. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF 2007 Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 5:183-193.
54. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY, Thakker RV 2007 Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26:1213-1221.
55. Hahn MA, Marsh DJ 2007 Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett 581:5070-5074.
56. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF 2005 Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24:1272-1276.
57. Zhang C, Kong D, Tan MH, Pappas DL Jr, Wang PF, Chen J, Farber L, Zhang N, Koo HM, Weinreich M, Williams BO, Teh BT 2006 Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun 350:17-24.
58. Iwata T, Mizusawa N, Taketani Y, Itakura M, Yoshimoto K 2007 Parafibromin tumor suppressor enhances cell growth in the cells expressing 5V40 large T antigen. Oncogene 26:6176-6183.
59. Mosimann C, Hausmann G, Basler K 2006 Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125:327-341.
60. Wang CA, Gaz RD 1985 Natural history of parathyroid carcinoma. Diagnosis, treatment and results. Am J Surg 149:522-527.
61. Schantz A, Castleman B 1973 Parathyroid carcinoma. A study of 70 cases. Cancer 31:600-605.
62. LiVolsi VA 1985 Pathology of the parathyroid gland. In: Barnes L (ed.) Surgical Pathology of the Head and Neck. Marcel Dekker, New York, NY, USA, p. 1487.
63. Apel RL, Asa SL 2002 The parathyroid glands. In: LiVolsi VA, Asa SL (eds.) Endocrine Pathology. Churchill Livingstone, Philadelphia, PA, USA, pp. 103-147.
64. Smith JF, Coombs RRH 1984 Histological diagnosis of carcinoma of the parathyroid gland. J Clin Pathol 37:1370-1378.
65. Sundelin K, Tullgren O, Famebo LO 1994 Clinical corse of metastatic parathyroid cancer. World J Surg 18:594-598.
66. Abbona GC, Papotti M, Gasparri G, Bussolati G 1995 Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 26:135-138.
67. Farnebo F, Auer G, Farnebo LO, Teh BT, Twigg S, Aspenblad U, Thompson NW, Grimelius L, Larsson C, Sandelin K 1999 Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg 23:68-74.
68. Vargas MP, Vargas HI, Kleiner DE, Merino MJ 1997 The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10:12-17.
69. Naccarato AG, Marcocci C, Miccoli P, Bonadio AG, Cianferotti L, Vignali E, Cipollini G, Viacava P 1998 Bc1-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Invest 21:136-141.
70. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV 1999 Parathyroid hyperplasia, adenomas, and carcinomas: Differential expression of p27Kip1 protein. Am J Surg Pathol 23:288-295.
71. Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H 2004 Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma. J Pathol 202:86-94.
72. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M 2005 Galectin-3 expression in parathyroid carcinoma: Immunohistochemical study of 26 cases. Hum Pathol 36:908-914.
73. Rubin MR, Silverberg SJ, D'Amour P, Brossard JH, Rousseau L, Sliney J Jr, Cantor T, Bilezikian JP 2007 An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem 53:1470-1476.
74. Fernandez-Ranvier GG, Jensen K, Khanafshar E, Quivey JM, Glastonbury C, Kebebew E, Duh QY, Clark OH 2007 Non-functioning parathyroid carcinoma: Case report and review of literature. Endocr Pract 13:750-757.
75. Stock JL, Weintraub BD, Rosen SW, Aurbach GD, Spiegel AM, Marx SJ 1982 Human chorionic gonadotropin subunit measurement in primary hyperparathyroidism. J Clin Endocrinol Metab 54:57-63.
76. Rubin MR, Bilezikian JP, Birken S, Silverberg SJ 2008 Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol 159:469-474.
77. Rubin MR, Silverberg SJ 2005 Editorial: HRPT2 in parathyroid cancer: A piece of the puzzle. J Clin Endocrinol Metab 90:5505-5507.
78. Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT 2004 Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629-6637.
79. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ 2006 Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140-1149.
80. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, Bränström R, Obara T, Arnold A, Larsson C, Höög A 2007 Parafibromin immunoreactivity: Its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14:501-512.
81. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Höög A, Villablanca A 2006 Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13:509-523.
82. Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S, Bilezikian JP, Pinchera A, Marcocci C 2008 Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest (in press).
83. Kebebew E 2001 Parathyroid carcinoma. Curr Treat Options Oncol 2:347-354.
84. Koea JB, Shaw JH 1999 Parathyroid cancer: Biology and management. Surg Oncol 8:155-165.
85. Sandelin K, Auer G, Bondeson L, Grimelius L, Famebo LO 1992 Prognostic factors in parathyroid cancer: A review of 95 cases. World J Surg 16:724-731.
86. Marcocci C, Mazzeo S, Bruno-Bossio G, Picone A, Vignali E, Ciampi M, Viacava P, Naccarato AG, Miccoli P, Iacconi P, Pinchera A 1998 Preoperative localization of suspicious parathyroid adenomas by assay of parathyroid hormone in needle aspirates. Eur J Endocrinol 139:72-77.
87. Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P 2000 Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 23:255-257.
88. Wang C, Gaz R 1983 Natural history of parathyroid carcinoma: Diagnosis, treatment and results. Am J Surg 149:522-527.
89. Anderson B, Samaan N, Vassilopoulou-Sellin R, Ordonez N, Hickey R 1983 Parathyroid carcinoma: Features and difficulties in diagnosis and management. Surgery 94:906-915.
90. Rawat N, Khetan N, Williams DW, Baxter JN 2005 Parathyroid carcinoma. Br J Surg 92:1345-1353.
91. Wynne A, Heerden JV, Carney J, Fitzpatrick L 1992 Parathyroid carcinoma: Clinical and pathological features in 43 patients. Medicine 71:197-205.
92. Rao SR, Shaha AR, Singh B, Rinaldo A, Ferito A 2002 Management of cancer of the parathyroid. Acta Otolaryngol 122:448-452.
93. Munson ND, Foote RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, van Heerden JA, Thompson GB, Lloyd RV 2003 Parathyroid carcinoma: Is there a role for adjuvant radiation therapy? Cancer 98:2378-2384.
94. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R 2004 Parathyroid carcinoma: Evaluation and interdisciplinary management. Cancer 100:900-905.
95. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM Jr, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R 2004 Parathyroid carcinoma: A 22-year experience. Head Neck 26:716-726.
96. Mulder JE, Bilezikian JB 2001 Acute management of hypercalcemia. In: Bilezikian JP, Marcus R, Levine MA (eds.) The Parathyroids. Basic and Clinical Concepts, 2nd ed. Academic Press, San Diego, CA, USA, pp. 729-741.
97. Koyano H, Shishiba Y, Shimizu T, Suzuki N, Nakazawa H, Tachibana S, Murata H, Furui S 1994 Successful treatment by surgical removal of bone metastasis producing PTH: New approach to the management of metastatic parathyroid carcinoma. Intern Med 33:697-702.
98. Denney AM, Watts NB 2004 The effect of octreotide on parathyroid carcinoma. J Clin Endocrinol Metab 89:1016.
99. Bradwell AR, Harvey TC 1999 Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353:370-373.
100. Shoback DM, Arends RH, Roskos L, Shetty S, Wyres M, Huang S, Raienbell GM 2004 Treatment of parathyroid carcinoma with ABX10241, a monoclonal antibody to parathyroid hormone. J Bone Miner Res 17:5A498.
101. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A 2004 Hormonal and biochemical normalization and tumor shrinkage induced by antiparathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413-3420.
102. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA 2000 Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300-306.
103. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045.
104. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 93:1083-1088.
105. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141.
106. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP 2007 Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803-3808.
107. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1999 Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1999: A National Cancer Database report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86:538-544.
108. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM 2007 Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736-1741.